论文部分内容阅读
美国FDA于2009年11月16日批准,经由美国Neuro-gesX生物制药公司生产的辣椒碱透皮贴剂上市。该药前身为NGX-4010,化学名称为(反)-N-[(4-羟基-3-甲氧基苯基)-甲基]-8-甲基6-壬烯基酸胺,化学式C_(18)H_(27)NO_3,分子量305.42,商品名Qutenza~(TM),是目前唯一具有处方药规格的辣椒碱透皮贴剂,主要用于治疗带状疱疹后神经痛(PHN),人免疫缺陷病毒(HIV)-1感染及进展性慢性疼痛所致的周围神经病变(HIV-DSP)。该药成分辣椒碱系人工合成,与辣椒中发现的天然成分等效。研究证实该药疗效肯定,安全
US FDA approved on November 16, 2009, through the United States Neuro-gesX biopharmaceutical company capsaicin transdermal patch. The drug is formerly known as NGX-4010 and has the chemical name of (trans) -N - [(4-hydroxy-3- methoxyphenyl) -methyl] (18) H_ (27) NO_3, molecular weight 305.42, trade name Qutenza TM, is the only capsaicinoid transdermal patch with prescription specifications and is mainly used for the treatment of post-herpetic neuralgia (PHN), human immunization Defective virus (HIV) -1 infection and progressive peripheral pain caused by chronic neuropathy (HIV-DSP). The drug ingredients capsaicin synthetic, and peppers found in the natural ingredients equivalent. Study confirmed that the drug efficacy is safe and secure